SPECTROSCOPY

Genedata Expressionist for Mass Spectrometry

31 March 2014

Genedata

Genedata, which provides software for drug discovery and life science research, has released the latest version of Genedata Expressionist for Mass Spectrometry (MS). A data analysis and management platform supporting all MS instrument vendors, Genedata Expressionist for MS eliminates data analysis bottleneck for MS labs.

This new version significantly improves MS lab productivity by accelerating the data analysis process for all major biopharmaceutical characterisation assays by orders of magnitude compared to common processing procedures the company claims.

The enterprise-level platform covers all biopharmaceutical applications including: characterisation of intact proteins; identification and characterisation of post-translational modifications; and characterisation and monitoring of impurities in protein samples.

Mass spectrometry plays an increasingly important role in the characterization of biopharmaceuticals. By providing a vendor-independent and enterprise-level software solution, Genedata Expressionist for MS enables scientists to use the same interface for a variety of MS assays and applications, which reduces the learning curve typically required for different software solutions. 

The new Genedata Expressionist for MS helps laboratories automate processes across the entire characterisation workflow from sample acquisition to result reporting. With intuitive visualisations and exceptional processing power and scalability, Genedata Expressionist enables quick integration and comparison of different experiments.

By supporting intact protein analysis, peptide mapping, N- and C-terminal analysis, glycopeptides and released glycans, and prediction of disulphide bonds, Genedata Expressionist for MS helps users with the analysis of the following MS-based applications:

  • Characterisation of Proteins

  • Characterisation of Post-Translational Modifications

  • Characterisation of Impurities

  • Comparability Analysis of Biotherapeutics

Click here to find out more